Enfermedad multivaso DES for multivessel PCI

Ajay-Kirtane
Ajay Kirtane
2011-08-04

More articles by this author

Esta es una entrada en ingles

demo en ingles

test eng

Download the Official SOLACI-CACI 2024 Congress APP

  DOWNLOAD THE OFFICIAL APP OF SOLACI-CACI 2024 Next Wednesday marks the beginning of SOLACI-CACI 2024! Download the Congress APP and discover the unmissable program of the...

Survey on Hemodynamics Centers in Latin America – SOLACI, Stent Save a Life! and South American Society of Cardiology Initiative

The treatment of ST-segment elevation myocardial infarction (STEMI) in Latin America is highly diverse. There are notable differences between countries and even among regions...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...